MedTech I.Q.

The Cutting Edge of Medical Technology Content, Community & Collaboration

Colleagues,

As reported in BioTech Transfer Week ... Seattle-based biotech investment and development firm Accelerator said this week that it has formed its 10th startup, Xori, which is developing a new technology for discovering and developing monoclonal antibodies for therapeutic use.

The technology will enable Xori to identify high-affinity mAbs "within a matter of weeks, as opposed to the more traditional methods, which require many months and often fail to generate high-quality reagents," ... Investors in the company's Series A investment include Accelerator partners Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.

Read on at: http://www.genomeweb.com/node/917105?emc=el&m=394474&l=5&am...

ENJOY!

CC

Views: 0

© 2024   Created by CC-Conrad Clyburn-MedForeSight.   Powered by

Badges  |  Report an Issue  |  Terms of Service